Xeris Biopharma (NASDAQ:XERS) Stock Price Up 5.7% – Here’s What Happened

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) shares were up 5.7% on Friday . The company traded as high as $3.60 and last traded at $3.55. Approximately 1,281,332 shares were traded during mid-day trading, a decline of 8% from the average daily volume of 1,395,790 shares. The stock had previously closed at $3.36.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on XERS. Piper Sandler cut shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price target for the company. in a report on Monday, November 11th. HC Wainwright increased their target price on Xeris Biopharma from $6.00 to $6.60 and gave the stock a “buy” rating in a report on Monday, November 11th.

Xeris Biopharma Trading Up 1.2 %

The company has a market capitalization of $506.88 million, a P/E ratio of -7.56 and a beta of 2.62. The firm’s 50 day moving average price is $3.35 and its two-hundred day moving average price is $2.91.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Xeris Biopharma during the 3rd quarter worth about $35,000. Quantbot Technologies LP acquired a new position in Xeris Biopharma during the third quarter valued at approximately $44,000. Asset Management Group Inc. grew its stake in Xeris Biopharma by 130.7% in the second quarter. Asset Management Group Inc. now owns 26,480 shares of the company’s stock valued at $60,000 after purchasing an additional 15,000 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Xeris Biopharma by 64.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 28,657 shares of the company’s stock worth $82,000 after purchasing an additional 11,239 shares during the last quarter. Finally, Goldstein Advisors LLC raised its stake in shares of Xeris Biopharma by 19.7% during the 3rd quarter. Goldstein Advisors LLC now owns 30,425 shares of the company’s stock worth $87,000 after purchasing an additional 5,000 shares in the last quarter. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.